Phase II randomized observer-blind trial of adjuvanted versus unadjuvanted A/California/7/2009 (H1N1)v-like influenza vaccine in adults

Phase 2, randomised, single-blind trial of Q-Pan H1N1 in influenza A virus infection (H1N1) (2 arms), sponsored by GSK. Primary endpoints: Humoral immune response in terms of haemagglutination inhibition antibodies and HI antibody response at 14 days after second dose. Started Jul 2009; status: completed.